申请人:Kowa Company, Ltd.
公开号:EP2426113A1
公开(公告)日:2012-03-07
It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. It is a carbinol compound represented by the following general formula (I) or salt thereof, or their solvate:
(wherein, each V and W independently show N or C-R7; each X and Y independently show CH2, C=O, SO2, etc.; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)
提供一种新型 LXRβ 激动剂,可作为动脉粥样硬化、动脉硬化(如糖尿病引起的动脉硬化)、血脂异常、高胆固醇血症、血脂相关疾病、由炎症细胞因子引起的炎症性疾病、皮肤病(如过敏性皮肤病)、糖尿病或阿尔茨海默病的预防和/或治疗药物。它是由以下通式(I)或其盐或它们的溶解物所代表的醇化合物:
(其中,V 和 W 各自独立地表示 N 或 C-R7;X 和 Y 各自独立地表示 CH2、C=O、SO2 等;Z 表示 CH 或 N;R1、R2 和 R7 各自独立地表示氢原子、C1-8 烷基等。R3 表示 C1-8 烷基;R4 表示任选取代的 C6-10 芳基或任选取代的 5 至 11 元杂环基团;R5 和 R6 表示氢原子等;L 表示任选被氧代基团取代的 C1-8 烷基链等;n 表示 0 至 2 的任意整数)。